2-(4-fluoro-phenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid | 1195782-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-fluoro-phenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid
• 英文别名: 2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid；1-(4-fluorophenyl)-2,3-dimethyl-5-oxopyrazole-4-carboxylic acid
• CAS: 1195782-84-3
• 化学式: C₁₂H₁₁FN₂O₃
• 分子量: 250.229
• InChiKey: DBVQFPOKBRTQMT-UHFFFAOYSA-N

物化性质

• 沸点：
  378.4±52.0 °C(Predicted)
• 密度：
  1.411±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  60.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-fluoro-phenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid 在 过氧乙酸 、 碳酸氢钠 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 2-(4-fluorophenyl)-1,5-dimethyl-4-(5-methylsulfonyl-1H-1,2,4-triazol-3-yl)pyrazol-3-one
  参考文献：
  名称：

  1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of Na V 1.7 inhibition

  摘要：

  Recently, the identification of several classes of aryl sulfonamides and acyl sulfonamides that potently inhibit Na(v)1.7 and demonstrate high levels of selectivity over other Na-v isoforms have been reported. The fully ionizable nature of these inhibitors has been shown to be an important part of the pharmacophore for the observed potency and isoform selectivity. The requirement of this functionality, however, has presented challenges associated with optimization toward inhibitors with drug-like properties and minimal off-target activity. In an effort to obviate these challenges, we set out to develop an orally bioavailable, selective Na(v)1.7 inhibitor, lacking these acidic functional groups. Herein, we report the discovery of a novel series of inhibitors wherein a triazolesulfone has been designed to serve as a bioisostere for the acyl sulfonamide. This work culminated in the delivery of a potent series of inhibitors which demonstrated good levels of selectivity over Na v 1.5 and favorable pharmacokinetics in rodents. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.04.035
• 作为产物：
  描述：

  benzyl 2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate 在 钯 作用下， 以 甲醇 、 氢气 为溶剂， 反应 8.0h， 以The target compound was yielded (1.8 g, 94% yield)的产率得到2-(4-fluoro-phenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR

  摘要：

  提供了一种新型杂环化合物，通过抑制生长因子受体蛋白激酶活性，如c-Met，可用作抗癌药物，以及含有该化合物的药物组合物和使用该化合物的方法。

  公开号：

  US20110183983A1

文献信息

• [EN] FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS ET LEUR UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009136663A1

  公开（公告）日：2009-11-12

  The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强烈激酶抑制活性的融合杂环衍生物及其用途。本发明涉及本说明书中所定义的符号表示的化合物，或其盐。
• [EN] NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS CONVENANT COMME INHIBITEURS DE C-MET TYROSINE KINASE
  申请人：ZHEJIANG BETA PHARMA INC

  公开号：WO2012006960A1

  公开（公告）日：2012-01-19

  Certain novel fused quinazoline derivatives of formula (I) as c-Met inhibitors, their synthesis and their uses for treating a c-Met mediated disorder. Methods for treating a c-Met-mediated disorder are also disclosed in the invention.

  某些新型融合喹唑啉衍生物的化学式（I），作为c-Met抑制剂，它们的合成以及用于治疗c-Met介导的疾病的用途。该发明还揭示了治疗c-Met介导疾病的方法。
• Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors
  申请人：Hu Shaojing

  公开号：US20130123286A1

  公开（公告）日：2013-05-16

  Certain novel fused quinazoline derivatives of formula (I) as c-Met inhibitors, their synthesis and their uses for treating a c-Met mediated disorder. Methods for treating a c-Met-mediated disorder are also disclosed in the invention.

  某些新型融合喹唑啉衍生物（化学式（I））作为c-Met抑制剂，它们的合成以及用于治疗c-Met介导的疾病的用途。该发明还公开了治疗c-Met介导的疾病的方法。
• FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF
  申请人：Miyamoto Naoki

  公开号：US20110046169A1

  公开（公告）日：2011-02-24

  The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强大的激酶抑制活性的熔合杂环衍生物及其使用。本发明涉及一种由式子所表示的化合物，其中每个符号如本说明书中所定义的，或其盐。
• Heterocyclic compound as protein kinase inhibitor
  申请人：Kim Tae-Seong

  公开号：US08957102B2

  公开（公告）日：2015-02-17

  Provided are novel heterocyclic compounds useful as anti-cancer drugs by suppressing protein kinase activities of growth factor receptors such as c-Met, pharmaceutical compositions containing the same, and methods for using the compound.

  提供了一种新型杂环化合物，通过抑制生长因子受体（如c-Met）的蛋白激酶活性，可用作抗癌药物。该药物组合物中包含该化合物，并提供使用该化合物的方法。